Investigating behaviour of polymers in nanoparticles of Chitosan Oligosaccharides coated with Hyaluronic Acid

Dey, Anomitra; Koli, Uday; Dandekar, Prajakta; Jain, Rekha

doi:10.1016/j.polymer.2016.04.027

Cited by 33 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HA is known to interact with CD44 (cluster of differentiation-44), receptor for hyaluronan-mediated motility, and lymphatic vessel endothelial receptor-1 cell surface receptors, which are overexpressed in tumor cells. 23 – 25 Activation of such receptors, upon HA–receptor interaction, can stimulate signal responses that promote internalization of chemotherapeutic agent-loaded NPs. 26 …”

Section: Introductionmentioning

confidence: 99%

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

Shen¹,

Li²

2018

DDDT

View full text Add to dashboard Cite

BackgroundAim of this study was to prepare the hyaluronic acid and human serum albumin modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation method.MethodsERT-HSA-HA NPs were characterized for physical properties, such as morphology and particle size, and in vitro drug release. Moreover, the cytotoxicity, cellular uptake, in vivo studies of ERT-HSA-HA nanoparticle were investigated and compared in A549 cells.ResultsThe ERT-HSA-HA NPs showed spherical morphology, and their hydrodynamic diameter was 112.5±2.8 nm. The drug loading amount and encapsulation efficiency were 5.6% and 81.2%, respectively. After 3 months of storage, no dramatic change, such as visible aggregation, drug content changes, and precipitation, in the appearance of ERT-HSA-HA NPs occurred. In vitro release showed that the release of ERT from HSA-HA NPs was slow, without obvious burst effects at an early stage. In in vivo studies, ERT-HSA-HA NPs showed a superior antiproliferative effect on A549 cells, and the HA modification strategy can also facilitate the high-efficiency uptake of ERT-HSA NPs by A549 cells. Pharmacokinetic studies showed that the form of NPs could significantly extend the role of ERT in vivo (provided higher bioavailability). However, there was no significant difference in the pharmacokinetic parameters between ERT-HSA NPs and ERT-HSA-HA NPs after intravenous administration. In terms of in vivo antitumor activity, ERT-HSA-HA NP-treated mice showed a significantly suppressed tumor growth and no relapse after 30 d of treatment.ConclusionHA/HSA co-modified erlotinib albumin nanoparticles was expected to be a new strategy in the treatment of lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

Shen¹,

Li²

2018

DDDT

View full text Add to dashboard Cite

show abstract

“…Chitosan is a biopolymer obtained through the deacetylation of chitin and employed for several biomedical applications including gene and drug delivery and treatment of wound infections, due to its unique properties such as biocompatibility, biodegradability, antimicrobial, antioxidant, and mucoadhesion characters. [34][35][36][37] Recently, engineered nanoparticles have been successfully applied in topical delivery systems. [38][39][40] In particular, ultra-small polymeric nanoparticles (smaller than 40 nm) show superior penetration into skin strata, carrying and delivering active molecules to the desired site of application.…”

Section: Introductionmentioning

confidence: 99%

Chitosan nanoparticles for nitric oxide delivery in human skin

et al. 2017

View full text Add to dashboard Cite

The use of nanoparticle-based transdermal delivery systems is a promising approach to efficiently carry and deliver therapeutic agents for dermal and systemic administration. Nitric oxide (NO) is a key molecule that plays important roles in human skin such as the control of skin homeostasis, skin defense, control of dermal blood flow, and wound healing. In addition, human skin contains stores of NO derivatives that can be mobilized and release free NO upon UV irradiation with beneficial cardiovascular effects, for instance the control of blood pressure. In this work, the NO donor precursor glutathione (GSH) was encapsulated (encapsulation efficiency of 99.60%) into ultra-small chitosan nanoparticles (CS NPs) (hydrodynamic size of 30.65 ± 11.90 nm). GSH-CS NPs have a core-shell structure, as revealed by atomic force microscopy and X-ray photoelectron spectroscopy, in which GSH is protected in the nanoparticle core. Nitrosation of GSH by nitrous acid led to the formation of the NO donor -nitrosogluthathione (GSNO) into CS NPs. The GSNO release from the CS NPs followed a Fickian diffusion described by the Higuchi mathematical model. Topical application of GSNO-CS NPs in intact human skin significantly increased the levels of NO and its derivatives in the epidermis, as assayed by confocal microscopy, and this effect was further enhanced by skin irradiation with UV light. Therefore, NO-releasing CS NPs are suitable materials for transdermal NO delivery to local and/or systemic therapies.

show abstract

“…To investigate the cellular uptake and intracellular drug release mechanism of sPEG/HA/CSO-SS-Hex/Fe 3 O 4 /GA, 4T1 cells (overexpressing CD44 receptor) incubated with FITC and NR (Nile red) (Hu et al., 2015 ) labeled sPEG/HA/CSO-SS-Hex/Fe 3 O 4 /GA, HA/CSO-SS-Hex/Fe 3 O 4 /GA and CSO-SS-Hex/Fe 3 O 4 /GA micelles (FITC-sPEG/HA/CSO-SS-Hex/Fe 3 O 4 /NR, FITC- HA/CSO-SS-Hex/Fe 3 O 4 /NR and FITC-CSO-SS-Hex/Fe 3 O 4 /NR) were observed by fluorescence microscope (Song et al., 2014 ; Dey et al., 2016 ). The results showed ( Figure 3(A) ) that the fluorescent intensity (FITC and NR) of 4T1 cells treated with FITC-sPEG/HA/CSO-SS-Hex/Fe 3 O 4 /NR (HA-) micelles was significantly stronger than those treated with FITC-sPEG/HA/CSO-SS-Hex/Fe 3 O 4 /NR (HA+) micelles, also the FITC- HA/CSO-SS-Hex/Fe 3 O 4 /NR micelles was stronger than those treated with FITC-CSO-SS-Hex/Fe 3 O 4 /NR micelles under the same imaging parameters throughout the cell imaging process.…”

Section: Resultsmentioning

confidence: 99%

A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer

et al. 2018

View full text Add to dashboard Cite

Gambogic acid (GA) is a naturally derived potent anticancer agent with extremely poor biocompatibility. In the present study, a novel of redox/pH dual-responsive multifunctional magnetic complex micelle (sPEG/HA/CSO-SS-Hex/Fe3O4/GA), which consisted of a reducible hexadecanol-modified chitosan oligosaccharide polymer micelle (CSO-SS-Hex) coated with hyaluronic acid (HA) and DCA grafted sheddable PEG-PLL (sPEG) copolymers and loaded with gambogic acid (GA) and Fe3O4 nanoparticles were developed for parenteral delivery for the treatment of triple negative breast cancer (TNBC). The ex vivo study showed that the sPEG shielded cationic HA/CSO-SS-Hex/Fe3O4/GA core at physiological pH but quickly shed off to re-expose the core due to its charge reversible property. The sPEG/HA/CSO-SS-Hex/Fe3O4/GA micelles effectively facilitated tumor-targeted GA delivery by HA, which is a targeting ligand for CD44 receptor of TNBC cells, meanwhile increase GA uptake at the acidic condition but diminished the drug uptake at neutral pH. The in vitro cellular uptake study and in vivo biodistribution and antitumor activity of the formulations were determined, all results showed that the complex micelle enhanced TNBC tumor cellular uptake and fast drug release due to the combined effect of magnet targeting, CD44 receptor-mediated internalization and redox/pH dual-responsive drug release. Hence, tumor-targeted delivery of GA with redox/pH dual-responsive multifunctional magnetic complex micelle sPEG/HA/CSO-SS-Hex/Fe3O4/GA might have potential implications for the chemotherapy of TNBC.

show abstract

Investigating behaviour of polymers in nanoparticles of Chitosan Oligosaccharides coated with Hyaluronic Acid

Cited by 33 publications

References 39 publications

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

Chitosan nanoparticles for nitric oxide delivery in human skin

A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer

Contact Info

Product

Resources

About

Investigating behaviour of polymers in nanoparticles of Chitosan Oligosaccharides coated with Hyaluronic Acid

Cited by 33 publications

References 39 publications

HA/HSA co-modified erlotinib&ndash;albumin nanoparticles for lung cancer treatment

HA/HSA co-modified erlotinib&ndash;albumin nanoparticles for lung cancer treatment

Chitosan nanoparticles for nitric oxide delivery in human skin

A novel redox/pH dual-responsive and hyaluronic acid-decorated multifunctional magnetic complex micelle for targeted gambogic acid delivery for the treatment of triple negative breast cancer

Contact Info

Product

Resources

About

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment